高级搜索
化疗相关性白细胞减少等因素对小细胞肺癌生存期的影响[J]. 肿瘤防治研究, 2009, 36(11): 961-965. DOI: 10.3971/j.issn.1000-8578.2009.11.016
引用本文: 化疗相关性白细胞减少等因素对小细胞肺癌生存期的影响[J]. 肿瘤防治研究, 2009, 36(11): 961-965. DOI: 10.3971/j.issn.1000-8578.2009.11.016
Impact of CIL on Survival of Patients with Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(11): 961-965. DOI: 10.3971/j.issn.1000-8578.2009.11.016
Citation: Impact of CIL on Survival of Patients with Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(11): 961-965. DOI: 10.3971/j.issn.1000-8578.2009.11.016

化疗相关性白细胞减少等因素对小细胞肺癌生存期的影响

Impact of CIL on Survival of Patients with Small Cell Lung Cancer

  • 摘要: 目的 探讨影响小细胞肺癌(small cell lung cancer, SCLC)患者生存期的因素。方法 回顾性研究123例SCLC患者的临床资料,利用SPSS15.0统计软件Cox回归模型分析性别、年龄、吸烟、合并症、临床分期、ECOG评分、治疗方法、CEA、化疗相关性白细胞减少(chemotherapy-induced leucopenia,CIL )9个预后因素对生存期的影响。结果 随访1~52月,死亡103例。6月、1年、2年、3年、4年存活率分别为70.7%、34.1%、8.94%、2.4%、0.8%,中位生存期11月95%CI(9.328, 12.627)。Cox回归多因素分析显示,影响预后的独立因素是:ECOG评分(P=0.000)、化疗联合放疗(P=0.000)、临床分期(P=0.024)、CIL(P=0.013)。结论 临床分期早、ECOG评分低、接受化疗联合放疗且出现CIL的SCLC患者生存期长、预后好。

     

    Abstract: Objective The objective of this study is to discuss the independent prognostic factors in the patients of smallcell lung cancer(SCLC). Methods One hundred and twenty-three patients of SCLC were reviewed. The potential prognostic factors such as: gender, age,smoke,complication,clinical stage, ECOG performance status,treatment,CEA,chemotherapy induced leucopenia(CIL) were analyzed by Cox regression using SPSS15.0 software. Results After 1 to 52 months follow-up,103 patients died. The surival rate in 6 month, 1st year, 2nd year, 3rd year and 4th year were 70.7%,34.1%,8.94%,2.4%and 0.8%,respectively. Median survival time(MST) was 11 months95%CI(9.328, 12.627).Cox regression showed that the independent prognostic factors on the surival time were ECOG performance status (P=0.000), chemoradiotherapy (P=0.000), clinical stage (P=0.024), and CIL (P=0.013). Conclusion Patients of SCLC, who are in limited clinic stage,with low ECOG performance status,have been treated with chemoradiotherapy and showed CIL, will prolong the survival time (P<0.05) and have a better life quality.

     

/

返回文章
返回